Table 2. Ongoing combination trials with DDR and immune checkpoint inhibitors (www.clinicaltrials.gov).
| ICI | Tumour group | Target population | DDR agent | Phase | Arms | Planned n | Trial status | NCT | Citation/remarks |
|---|---|---|---|---|---|---|---|---|---|
| Durvalumab | Breast | 3rd line | Olaparib | 1/2 | Olaparib + Durvalumab | 133 | Recruiting | NCT02734004 | |
| Gastric | 2nd line | ||||||||
| Ovarian | Platinum sensitive | ||||||||
| SCLC | 2nd line | ||||||||
| NSCLC/ SCLC | 2nd or higher line | Olaparib | 1/2 | Durvalumab + Olaparib | 338 | Recruiting | NCT02484404 | ||
| Breast | TNBC, < 3 prior lines | Durvalumab + Cediranib | |||||||
| Ovarian | Platinum resistant | Durvalumab + Olaparib + Cediranib | |||||||
| Colorectal | 3rd line | ||||||||
| Prostate | mCRPC | ||||||||
| Ovary | gBRCA | Olaparib | 1/2 | Olaparib + Durvalumab + Tremelimumab | 39 | Not yet recruiting | NCT02953457 | ||
| NSCLC | Refractory | AZD6738 | 1 | AZD6738 + Durvalumab | 114 | Recruiting | NCT02264678 | Has other arms involving AZD 6738 with other agents | |
| HNSCC | |||||||||
| Tremelimumab | Ovarian | 2nd line + | Olaparib | 1/2 | Tremelimumab + Olaparib | 50 | Recruiting | NCT02571725 | gBRCA only |
| Pembrolizumab | Breast | Up to 3 prior lines | Niraparib | 1/2 | niraparib + pembrolizumab | 114 | Recruiting | NCT02657889 | TNBC only |
| Ovarian | Up to 4 prior lines | Platinum resistant/refractory only | |||||||
| Nivolumab | NSCLC | 1st line metastatic | Carboplatin + paclitaxel or pemetrexed + Veliparib | 2 | Veliparib + nivolumab + platinum doublet chemotherapy | 184 | Recruiting | NCT02944396 | NA |
| Veliparib + platinum doublet chemotherapy | |||||||||
| Adv solid tumours | Refractory to std therapy | Veliparib | 1 | Veliparib + Nivolumab | 50 | Not yet recruiting | NCT03061188 | ||
| Atezolizumab | Breast | Any prior therapy allowed | Veliparib | 2 | Veliparib | 90 | Recruiting | NCT02849496 | TNBC + gBRCA only |
| Atezolizumab | |||||||||
| veliparib + atezolizumab | |||||||||
| BGB-A317 | Adv solid tumours | 2nd line + | BGB-290 | 1 | BGB-A317 + BGB-290 | 124 | Recruiting | NCT02660034 |
Abbreviations: DDR=DNA damage response; gBRCA=germline BRCA; HNSCC=head and neck squamous cell cancer; ICI=immune checkpoint inhibitor; mCRPC=metastatic castration-resistant prostate cancer; NA=not available; NSCLC=non-small-cell lung cancer; SCLC=small-cell lung cancer; TNBC=triple-negative breast cancer.